GW Pharmaceuticals (London, UK, and Carlsbad, CA), along with US subsidiary Greenwich Biosciences, today announced that it has completed the rolling submission of a New Drug Application (NDA) to FDA for Epidiolex (cannabidiol) as adjunctive treatment of seizures associated with Lennox-Gastaut syOriginal Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.